Advertisement

Specialty News

April 13, 2016
April 13, 2016
**
MORE
January 13, 2016
January 13, 2016
The new year started with one FDA-approved biosimilar drug on the market and at least five others in the pipeline. The newcomers represent an...
Biosimilars Primer
MORE
January 13, 2016
January 13, 2016
Psoriasis is a chronic inflammatory skin disorder that typically causes patients to experience redness, scaling, and/or itching due to an autoimmune...
Specialty Pharmacy Section
MORE
January 13, 2016
January 13, 2016
In November 2015, FDA approved two first-in-class injectable agents for multiple myeloma: daratumumab (Darzalex—Janssen Biotech), a human CD38-...
New Drug
MORE
January 12, 2016
January 12, 2016
FDA’s Kimberly W. Chiu, PharmD, and Lena Y. Choe, PharmD, gave a presentation at the 2015 American Society of Health-System Pharmacists Midyear...
FDA Update
MORE
December 01, 2015
November 23, 2015
For health systems to survive in the changing health care landscape, data are crucial. Hospital programs and departments must continually prove...
Health-System Edition
MORE
November 01, 2015
October 28, 2015
FDA recently approved a combination medication, trifluridine/tipiracil (Lonsurf—Taiho Oncology), for patients with refractory colorectal cancer. The...
New Drug
MORE
November 01, 2015
October 27, 2015
In a case series published this September in JAMA, genetic testing in 91 children and young adults with refractory or relapsed cancer led to...
Health-System Edition
MORE
October 01, 2015
October 01, 2015
Prescribers in the United States currently have one FDA-approved biosimilar drug available to them: filgrastim-sndz (Zarxio—Sandoz). Ten or more are...
Comments due October 27
MORE
October 01, 2015
October 01, 2015
Open enrollment for Medicare Part D begins on October 15, 2015, and ends on December 7, 2015. CMS has released revisions to Part D that will take...
Key changes for pharmacists and their patients
MORE

Pages